ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#04

June 2026

Your Patients Are Asking About Ozempic and Cravings. Here Is What the Evidence Shows.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) were developed for type 2 diabetes and obesity, but emerging data show they also modulate mesolimbic dopamine signaling, the same reward pathway that drives compulsive substance use. A 2024 analysis of 33,006 patients with type 2 diabetes and opioid use disorder found semaglutide was associated with a 42 to 68% lower risk of opioid overdose compared with other antidiabetic medications during a one-year follow-up. A Washington University study published March 2026 found craving reduction across all major addictive substance categories studied, including opioids, alcohol, nicotine, and cannabis.

These medications are not FDA-approved for any substance use disorder indication. The available data come primarily from observational studies. Randomized controlled trials in SUD populations are underway but not yet reporting. The clinical relevance for OTP providers is immediate: many patients on buprenorphine or methadone carry metabolic comorbidities and may already be prescribed semaglutide or tirzepatide by their primary care provider without the OTP being informed.

Taplin DL, et al. Semaglutide and Opioid Overdose Risk. PMC. 2024. PMCID: PMC11425147  ·  Washington University School of Medicine. WashU Medicine News. March 2026.

In effect: February 16, 2026

42 CFR Part 2 Civil Enforcement Is Active. Penalties Now Align With HIPAA.

Effective February 16, 2026, the HHS Office for Civil Rights began accepting complaints under 42 CFR Part 2, the federal regulation governing confidentiality of substance use disorder treatment records. Penalties now align with HIPAA: $141 to $2.1 million per violation depending on culpability, with the same tiered structure. This is not a proposed rule. Enforcement is live.

The 2024 CARES Act amendments significantly changed Part 2. The new framework includes a single-consent model allowing SUD records to be used for treatment, payment, and healthcare operations without separate authorizations, updated breach notification requirements aligned with HIPAA, and prohibition on use of SUD records in criminal proceedings without patient consent. Many OTP programs updated their consent forms for the 2024 amendments but have not yet completed HIPAA-aligned breach notification procedures or staff training for the civil enforcement phase.

Three practical checks for OTP programs: (1) Consent forms reflect the single-consent model and explicitly cover treatment, payment, and operations. (2) A breach notification procedure exists and staff know it. (3) Any disclosures for research, audit, or evaluation use the updated authorization language. If you are consulting with OTP programs on compliance, this is the active issue.

HHS Office for Civil Rights. 42 CFR Part 2 Civil Enforcement. Effective February 16, 2026.  ·  Foley Hoag Analysis

FDA / FEDERAL REGISTER

FDA Clarifies: There Is No Maximum Dose for Buprenorphine Products

The FDA issued a Federal Register notice clarifying that existing buprenorphine product labeling "may be misinterpreted" as establishing a maximum dose, when no such maximum exists in the approved labeling. The clarification was prompted in part by clinician confusion when managing patients with high fentanyl tolerance who present with unresolved withdrawal at standard doses. The notice reinforces that clinical judgment governs dosing, and that prescribers should not be constrained by an implied ceiling that the FDA did not intend.

This matters practically for OTPs managing patients transitioning from high-potency synthetic opioids. A patient with heavy fentanyl use history presenting with inadequate buprenorphine response at 24 mg/day is not at the ceiling of what the FDA permits. The literature on high-dose buprenorphine induction (32 mg and above) in this population is supportive, and the FDA's notice removes the labeling ambiguity that was sometimes cited as a barrier.

FDA. Federal Register Notice: Buprenorphine Product Labeling Clarification. 2026.  ·  AMA summary →